DEF 14A: Amgen's 2024 Proxy Statement: Board Nominees, Executive Pay, and Equity Incentive Plan on the Agenda

Amgen's 2024 proxy statement outlines key proposals for the annual meeting, including director elections, executive compensation approval, and an amendment to the equity incentive plan.

Summary

• Amgen's 2024 Annual Meeting of Stockholders will be held virtually on May 31, 2024.
• Stockholders will vote on electing 12 directors, approving executive compensation, approving the Second Amended and Restated 2009 Equity Incentive Plan, and ratifying the selection of Ernst & Young LLP as the independent registered public accountants.
• The Board recommends voting for all director nominees, the executive compensation proposal, the equity incentive plan amendment, and the auditor ratification.
• The company's strategy focuses on innovation, branded biosimilars, global impact, manufacturing excellence, continuous improvement, and return of capital.
• In 2023, Amgen completed the acquisition of Horizon Therapeutics for $27.8 billion, establishing a fourth therapeutic pillar in rare diseases.
• The company's environmental sustainability goals include achieving carbon neutrality in operations by 2027, reducing water use by 40%, and reducing waste disposed by 75%.
• Amgen's executive compensation program is designed to reward long-term performance and align executive interests with those of stockholders.
• A significant portion of executive compensation is at risk and dependent on performance against pre-established goals.
• The Board is asking stockholders to approve an increase of 31,297,000 shares to the equity incentive plan to retain key employees and align their goals with stockholders' interests.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Amgen, highlighting strong financial performance, strategic acquisitions, and commitment to innovation and sustainability. The tone is optimistic and confident, reflecting a well-managed and successful company.

Positives

• Amgen delivered strong performance in 2023 and advanced its innovative pipeline.
• The acquisition of Horizon Therapeutics establishes a fourth therapeutic pillar and has significant growth potential.
• The company is committed to environmental sustainability with ambitious goals for 2027.
• Amgen has a strong record of returning capital to stockholders through dividends.
• The executive compensation program is designed to align executive interests with those of stockholders and reward long-term performance.
• The company has implemented compensation best practices, including stock ownership guidelines and a clawback policy.

Risks

• The document mentions risks associated with product development, safety and surveillance, supply and quality, value and access, sales and promotion, business development, and protecting assets (financial, intellectual property, and information, including cybersecurity and artificial intelligence).
• The document mentions risks associated with the integration of Horizon Therapeutics.

Future Outlook

Amgen plans to continue its valuable dialogue with investors in the coming year and looks forward to the Annual Meeting on May 31.

Management Comments

• Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President, stated that Amgen's mission has been to serve patients and, in 2023, their medicines reached more than 11 million patients around the world.
• Bradway also noted that the core of Amgen's strategy is innovation and that they seek to provide firstor best-in-class medicines that make a significant difference for patients suffering from serious diseases.
• Bradway thanked Drs. Ronald D. Sugar and R. Sanders Williams, who will retire from the Board and are not standing for re-election at the Annual Meeting, for their years of wise counsel and guidance to Amgen.

Industry Context

The document highlights Amgen's competitive position in the biotechnology and pharmaceutical industry, emphasizing its focus on innovation and strategic acquisitions to strengthen its portfolio.

Comparison to Industry Standards

• The document compares Amgen's executive compensation practices to those of a peer group consisting of biotechnology and pharmaceutical companies, including AbbVie, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche Holding, and Sanofi.
• The document mentions that Amgen uses market median values as the reference point for compensation at all job levels, including NEOs.
• The document mentions that Amgen's LTI equity award mix is 80% performance-based, with 50% in three-year performance units and 30% in stock options, which is aligned with industry best practices.
• The document mentions that Amgen's stock ownership guidelines for executives are designed to align their interests with those of stockholders, which is a common practice among publicly traded companies.

Related Party Transactions

• Leandro Grimaldi, son-in-law of an executive officer, is employed by Amgen.

Stakeholder Impact

• The document highlights Amgen's commitment to serving patients and improving access to medicines.
• The company's environmental sustainability goals benefit the environment and the communities where it operates.
• The executive compensation program is designed to align executive interests with those of stockholders.
• The company's human capital management practices aim to attract, motivate, develop, and retain top talent.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• Amgen will hold its Annual Meeting of Stockholders on May 31, 2024.
• The company will continue to engage with stockholders and solicit their perspectives.
• Amgen will continue to execute its strategy and pursue its environmental sustainability goals.

Key Dates

Keywords

Amgen, Annual Meeting, Proxy Statement, Executive Compensation, Board of Directors, Equity Incentive Plan, Horizon Therapeutics, Carbon Neutrality, Director Nominees, Financial Performance, Stockholders, Governance, Sustainability, Innovation, Biosimilars